GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Price-to-Tangible-Book

Defence Therapeutics (XCNQ:DTC) Price-to-Tangible-Book : (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Price-to-Tangible-Book?

As of today (2024-05-26), Defence Therapeutics's share price is C$1.20. Defence Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was C$-0.05. Hence, Defence Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Defence Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 3 years, Defence Therapeutics's highest Price to Tangible Book Ratio was 110.32. The lowest was 45.78. And the median was 67.50.

XCNQ:DTC's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.79
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Defence Therapeutics's share price is C$1.20. Defence Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was C$-0.05. Hence, Defence Therapeutics's P/B Ratio of today is .


Defence Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Defence Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Price-to-Tangible-Book Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Price-to-Tangible-Book
- 45.78 -

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 110.32 - -

Competitive Comparison of Defence Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Defence Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Defence Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Price-to-Tangible-Book falls into.



Defence Therapeutics Price-to-Tangible-Book Calculation

Defence Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.20/-0.052
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Defence Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Defence Therapeutics (XCNQ:DTC) Business Description

Traded in Other Exchanges
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director